{
  "id": 7042140,
  "title": "Combination therapy does not meet primary endpoints in first-line PD-L1-high metastatic non-small cell lung cancer",
  "url": "https://urgent.news/2026/09/13/combination-therapy-does-not-meet-primary-endpoints-in-first-line-pd",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-13T01:50:05.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-09-combination-therapy-primary-endpoints-line.html"
  },
  "original_language": "en",
  "account": "A recent phase 3 trial demonstrated that sacituzumab govitecan combined with pembrolizumab did not improve progression-free survival compared to pembrolizumab alone in patients with metastatic non-small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score of 50% or higher. While the combination therapy showed a higher response rate, the difference in progression-free survival did not meet statistical significance. Overall survival also did not improve significantly when comparing the combined treatment to pembrolizumab monotherapy at the interim analysis. The study enrolled 620 patients and found higher treatment-related adverse events with the combination, including anemia, alopecia, neutropenia, diarrhea, and nausea.",
  "summary": "Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score (TPS) of 50% or greater, according to primary results from the phase 3 EVOKE-03/KEYNOTE-D46 trial presented…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Medical Xpress",
        "title": "Combination therapy may improve immune response against advanced prostate cancer",
        "url": "https://urgent.news/2026/09/10/combination-therapy-may-improve-immune-response-against-advanced",
        "published": "2026-09-10T19:00:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}